Oral propranolol therapy in 23 infants with infantile hemangioma

Background Infantile hemangioma (IH) is a common vascular tumor in pediatric patients, and is commonly treated with propranolol. We describe our experiences with dosage, response to treatment, and side effects in 23 IH patients treated with propranolol.

Methods For this nonrandomized comparative cohort study, the authors enrolled 23 patients treated with propranolol. Photographs were taken before propranolol administration and at 3, 6, 9, and 12 months after treatment. Treatment responses were objectively analyzed with a computer program.

Results There were three male and 20 female patients. Common tumor locations were the head and neck (13 cases, 56.5%), trunk (four cases, 17.4%), extremities (three cases, 13.0%), and combined locations (three cases, 13.0%). The response to propranolol was significantly lower in patients with two or more lesions than in patients with a single lesion in terms of both color fading (P<0.001) and size reduction (P<0.001). In male patients (42.2±3.9), the change in a-values, indicating coloration, was higher than in female patients (19.8 ±13.8)(P<0.001). In patients who started treatment before 6 months after birth, the size reduction was greater than in their counterparts (62.3%; range, 3.0%–93.0% vs. 15.8%; range, 1.0%–79.0%; P<0.001).

Conclusions Propranolol is an efficacious treatment with a good safety profile. In patients with a single lesion, the response to treatment was better in terms of color fading and size reduction. Furthermore, male patients responded better to propranolol treatment in terms of color fading than female patients, and starting treatment before 6 months after birth was more advantageous for size reduction.

Keywords

Hemangioma - Propranolol - Therapeutics

Publication History

Received: 17 April 2018

Accepted: 18 October 2018

Article published online:
03 April 2022

• REFERENCES

• 1 Schupp CJ, Kleber JB, Gunther P. et al. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome. Pediatr Dermatol 2011; 28: 640-4
• 2 Haggstrom AN, Drolet BA, Baselga E. et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006; 118: 882-7
• 3 Ogawa R, Neligan PC. Benign cutaneous and soft-tissue tumors. Ogawa R. Benign and malignant nonmelanocytic tumors of the skin and soft tissue. Edinburgh: Elsevier Health Sciences; 2018: 707-42
• 4 Dubois J, Alison M. Vascular anomalies: what a radiologist needs to know. Pediatr Radiol 2010; 40: 895-905
• 5 Nakayama H. Clinical and histological studies of the classification and the natural course of the strawberry mark. J Dermatol 1981; 8: 277-91
• 6 North PE, Waner M, Mizeracki A. et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 2001; 137: 559-70
• 7 Sirachainan N, Lekanan W, Thammagasorn Y. et al. Response to propranolol in infantile hemangioma. Pediatr Int 2016; 58: 662-5
• 8 Barrio VR, Drolet BA. Treatment of hemangiomas of infancy. Dermatol Ther 2005; 18: 151-9
• 9 Enjolras O, Breviere GM, Roger G. et al. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr 2004; 11: 99-107
• 10 Zarem HA, Edgerton MT. Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg 1967; 39: 76-83
• 11 Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 2002; 138: 1567-76
• 12 Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J. et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372: 735-46
• 13 Leaute-Labreze C, Boccara O, Degrugillier-Chopinet C. et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics 2016; 1384: e20160353
• 14 Ji Y, Chen S, Xu C. et al. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol 2015; 172: 24-32
• 15 Aletaha M, Salour H, Bagheri A. et al. Oral propranolol for treatment of pediatric capillary hemangiomas. J Ophthalmic Vis Res 2012; 7: 130-3
• 16 Holland KE, Frieden IJ, Frommelt PC. et al. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 2010; 146: 775-8
• 17 International Color Consortium. Image technology colour management: architecture, profile format, and data structure. dSpecification ICC. 1: 2004-10 (Profile version 4.2. 0.0) [Internet]. Reston, VA: ICC; 2004. [cited 2018 Nov 7]. Available from http://www.color.org/icc1v42_2006-05.pdf
• 18 Izadpanah A, Izadpanah A, Kanevsky J. et al. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg 2013; 131: 601-13
• 19 Helfand M, Peterson K. Drug class review on beta adrenergic blockers. Portland: Oregon Health & Science University; 2005
• 20 Nguyen J, Fay A. Pharmacologic therapy for periocular infantile hemangiomas: a review of the literature. Semin Ophthalmol 2009; 24: 178-84
• 21 Denoyelle F, Leboulanger N, Enjolras O. et al. Role of propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol 2009; 73: 1168-72
• 22 Kim KM. et al. Propranolol as a first-line treatment for pediatric hemangioma: outcome of a single institution over one year. Clinical Pediatric Hematology-Oncology 2016; 23: 97-104
• 23 Wedgeworth E, Glover M, Irvine AD. et al. Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol in the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. Br J Dermatol 2016; 174: 594-601
• 24 Fost NC, Esterly NB. Successful treatment of juvenile hemangiomas with prednisone. J Pediatr 1968; 72: 351-7
• 25 Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999; 104: 1616-23